Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoats Group Plc Regulatory News (COA)

Share Price Information for Coats Group Plc (COA)

Share Price is delayed by 15 minutes
Get Live Data
76.70    -0.05 (-0.07%)
Bid:
76.95
Ask:
77.10
Spread: 0.15 (0.195%)
Market Cap: £1.47b
COA Live PriceLast checked at - London Stock Exchange

Intraday Coats Group Plc Share Chart

Lower Passaic River

7 Mar 2016 07:00

RNS Number : 1823R
Coats Group PLC
07 March 2016
 

07 March 2016

 

 

Coats Group plc

('Coats' or the 'Company')

 

Lower Passaic River

 

 

On 4 March 2016, the United States Environmental Protection Agency (EPA) announced a final record of decision for remediation of the lower 8 miles of the Lower Passaic River (LPR). That remedy is estimated by EPA on a net present value basis to be US$1.38 billion (reduced from EPA's original proposed remedy of US$1.73 billion on a net present value basis), which costs are anticipated to be shared among hundreds of potentially responsible parties.

 

For reasons reflected in prior disclosures, the Company believes that its share of remedial costs on the LPR is de minimis and that certain other companies should have a more significant share of remedial costs. Previously the Company had provided for the entire 17 mile stretch of the LPR on the basis of a de minimis share of an approximately US$0.7 billion Sustainable Remedy that had been proposed to EPA by a group of companies known as the Cooperating Parties Group (CPG), of which the Company is a member. In light of EPA's selection of a remedy for the lower 8 miles of the LPR, the Company has estimated that the loss attributable to equity shareholders of the Company for the entire 17 mile stretch of the LPR for the year ended 31 December 2015 will increase by approximately US$4 million compared to the unaudited results previously announced in the Company's Preliminary Announcement on 25 February 2016. This additional charge reflects the same de minimis share of the larger EPA remedy, takes into account insurance reimbursements and will be disclosed as an exceptional item consistent with the charge already recognised in the 2015 results. The pre-tax impact is estimated to be approximately US$7 million. The additional charge will result in a 0.31 cents negative impact on both earnings per ordinary share from continuing operations and loss per ordinary share from continuing and discontinued operations (both on a post-exceptional basis). This charge, including its impact on relevant balance sheet lines, will be incorporated into the Company's Annual Report to be issued on 10 March 2016. 

 

Negotiations among the parties and with EPA, remedial design and implementation of remedial action are expected to take more than 10 years. Additional revisions may be appropriate depending on future developments.

 

 

 

 

 

Enquiry details

Investors

Jaideep Thatai

Coats Group plc

+44 (0)20 8210 5086

Media

UK

Richard Mountain

FTI Consulting

+44 (0)20 3727 1374

NZ & Australia

Geoff Senescall

Senescall Akers

+64 9 309 5659

_________________________________________________________________________________

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFIFVVIRIIR
Date   Source Headline
9th May 20252:33 pmRNSHolding(s) in Company
29th Apr 20251:26 pmRNSHolding(s) in Company
8th Apr 20252:58 pmRNSBlock listing Interim Review
7th Apr 20251:18 pmRNSDirector/PDMR Shareholding
3rd Apr 20257:00 amRNSStrategic exit from US Yarns
21st Mar 20252:21 pmRNSDirector/PDMR Shareholding
17th Mar 20252:00 pmRNSDirector/PDMR Shareholding
13th Mar 20253:20 pmRNSDirector/PDMR Shareholding
13th Mar 20257:19 amRNSAnnual Financial Report
10th Mar 20254:02 pmRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNS2024 Full Year Results
7th Jan 20257:00 amRNSDirectorate Change
2nd Jan 20259:00 amRNSDirector Declaration
17th Dec 20241:16 pmRNSDirector/PDMR Shareholding
16th Dec 202411:04 amRNSDirector/PDMR Shareholding
20th Nov 20247:00 amRNSTrading Statement
15th Oct 202412:41 pmRNSBlock listing Interim Review
9th Oct 20243:16 pmRNSDirector/PDMR Shareholding
17th Sep 202411:11 amRNSHolding(s) in Company
16th Sep 20241:19 pmRNSHolding(s) in Company
12th Sep 20249:37 amRNSHolding(s) in Company
6th Sep 20242:00 pmRNSDirector/PDMR Shareholding
5th Sep 20242:00 pmRNSDirector Declaration
4th Sep 20247:00 amRNSFinal de-risking of UK pension scheme
13th Aug 20241:15 pmRNSHolding(s) in Company
12th Aug 20247:00 amRNSDirectorate Change
1st Aug 20247:00 amRNSHalf-year Report
30th May 20247:00 amRNSDirectorate Change
22nd May 20244:33 pmRNSResult of AGM
22nd May 20247:00 amRNSTrading Statement
7th May 20241:16 pmRNSHolding(s) in Company
5th Apr 202410:50 amRNSBlock listing Interim Review
25th Mar 20242:16 pmRNSDirector/PDMR Shareholding
25th Mar 20242:15 pmRNSDirector/PDMR Shareholding
13th Mar 20243:55 pmRNSAnnual Financial Report
8th Mar 202412:27 pmRNSDirector/PDMR Shareholding
8th Mar 202412:25 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNS2023 Full Year Results
29th Feb 202410:03 amRNSHolding(s) in Company
29th Feb 20249:59 amRNSHolding(s) in Company
14th Dec 20232:13 pmRNSDirector Declaration
7th Dec 20237:00 amRNSSwitch off of Pension Deficit Repair Payments
22nd Nov 20237:00 amRNSTrading Statement
21st Nov 20239:22 amRNSHolding(s) in Company
16th Nov 20232:02 pmRNSHolding(s) in Company
15th Nov 20239:00 amRNSChange of Senior Independent Director
1st Nov 20231:38 pmRNSHolding(s) in Company
9th Oct 202312:10 pmRNSBlock listing Interim Review
5th Oct 20237:00 amRNSDirectorate Change
27th Sep 202312:32 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.